Continuing Pharmacy Education / CE Master List / Immunization: These go to “11”-Vaccine Boosters for the Amplification of Immunity-Recorded Webinar
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Immunization: These go to “11”-Vaccine Boosters for the Amplification of Immunity-Recorded Webinar

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

·       Explain how the immune system responds to a booster dose of a vaccine
·       Concisely explain the clinical outcome data supporting administration of COVID-19 3rd doses and/or booster doses
·       Given a specific patient case, determine whether they would qualify for a COVID-19 vaccine booster dose and recommend an appropriate product to administer.

Release and Expiration Dates

Released:  December 20, 2021
Expires:  December 17, 2024

Course Fee

$15 Pharmacist

ACPE UAN

0009-0000-21-057-H06-P

Session Code

21RW57-KXV39

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-21-057-H06-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Jeffery Aeschlimann, PharmD
Associate Clinical Professor-Infectious Disease Specialty
University of Connecticut School of Pharmacy
Storrs, CT              

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Jeffery Aeschlimann has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

POST TEST

1. A 50 year old female (she/her) comes to your pharmacy. You know her well, as she frequently picks up prescriptions for a variety of medications, including immunosuppressants (she had a kidney transplant approximately five years ago). You note that she completed her 2-dose primary series of Comirnaty (the Pfizer-BioNTech COVID-19 Vaccine) approximately two months ago. She has not received any additional vaccinations of any kind since that time. What is the BEST course of action at this time? a. Offer to administer a third dose of Comirnaty COVID-19 vaccine b. Offer to administer a dose of the Johnson & Johnson/Janssen COVID-19 vaccine c. Remind her that she will need a booster dose of any COVID-19 vaccine in 4 months 2. People who have no detectable serum antibody response to the COVID-19 vaccines still appear to have approximately 50% protection from COVID-19 infection compared to unvaccinated people. a. True b. False 3. For people who have only received a primary series of COVID-19 mRNA vaccine, protection from severe COVID-19 disease (i.e., hospitalization due to COVID-19 infection) currently (in late December 2021) appears to be higher for people who received Pfizer vaccine than for Moderna vaccine recipients. a. True b. False 4. Which ONE of the following adverse effects appears to occur at a substantially HIGHER frequency for booster doses of both mRNA vaccines (as compared to 2nd doses of the primary series) a. Fever b. Lymphadenopathy c. Nausea/vomiting 5. A 75 year old male (he/him) comes to the pharmacy to pick up a prescription. He strikes up a conversation with you and you learn the following: • He received a dose of the Janssen/J&J vaccine in April 2021 • He hasn’t received any other COVID-19 vaccination since then • He is interested in getting a “booster dose” of COVID-19 vaccine Is he currently eligible to receive a booster dose? a. Yes b. No 6. According to the CDC & ACIP, which would be the preferred type of vaccine booster to administer (considering both overall effectiveness and safety)? a. An adenovirus vector COVID-19 vaccine (i.e., Janssen/J&J) b. A mRNA COVID-19 vaccine (i.e., Pfizer or Moderna) c. A second dose of whatever the patient received previously

Handouts

Download

VIDEO